India, March 10 -- The share of this company, which operates several US FDA-approved manufacturing facilities in India (Vadodara, Baddi, Panelav) and has a strong R&D focus, gained investor traction after announcing a stake acquisition by DII.

With a market capitalization of Rs 37,820 crore, Anthem Biosciences Ltd's share made a day high of Rs 686.70 per share, up by 4 percent from its previous day's close price of Rs 660 per share. The share of this company has given a negative return of 11 percent since its listing in July 2025.

News Viridity Tone LLP, backed by the private equity firm True North, has sold a 3.6 percent stake in Anthem Biosciences through open-market transactions worth about Rs 1,262 crore. The firm sold around 2.03 c...